CN111419891B - Sunflower disc extract and medical application thereof in constipation treatment - Google Patents

Sunflower disc extract and medical application thereof in constipation treatment Download PDF

Info

Publication number
CN111419891B
CN111419891B CN202010409447.XA CN202010409447A CN111419891B CN 111419891 B CN111419891 B CN 111419891B CN 202010409447 A CN202010409447 A CN 202010409447A CN 111419891 B CN111419891 B CN 111419891B
Authority
CN
China
Prior art keywords
sunflower disc
reacting
group
hour
dose group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202010409447.XA
Other languages
Chinese (zh)
Other versions
CN111419891A (en
Inventor
高波
张守琳
康明
葛振龙
杨茂君
韩葳葳
李婉南
韩璐
赵海峰
常浩
周喜鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Special Medical Food Biotechnology Co ltd
Jilin University
Original Assignee
Jilin Special Medical Food Biotechnology Co ltd
Jilin University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin Special Medical Food Biotechnology Co ltd, Jilin University filed Critical Jilin Special Medical Food Biotechnology Co ltd
Priority to CN202010409447.XA priority Critical patent/CN111419891B/en
Priority to AU2020101274A priority patent/AU2020101274A4/en
Publication of CN111419891A publication Critical patent/CN111419891A/en
Application granted granted Critical
Publication of CN111419891B publication Critical patent/CN111419891B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a sunflower disc extract and application thereof in constipation treatment, wherein the preparation process of the sunflower disc extract comprises the steps of adding water into a powdery sunflower disc, soaking for a certain time, heating to 45-55 ℃, adding cellulase, reacting for 1-4 hours, adding proteolytic enzyme (alkaline protease and neutral protease), reacting for 1-2 hours, finally adding flavourzyme, reacting for 1-2 hours, filtering while hot, concentrating, drying into powder or preparing into particles. The extraction rate of small molecular peptide and polysaccharide in the sunflower disc extract is greatly increased. The sunflower disc extract can treat constipation, and animal experiments and crowd trials prove that the invention can obviously promote defecation of patients and has no toxic or side effect.

Description

Sunflower disc extract and medical application thereof in constipation treatment
Technical Field
The invention discloses a sunflower disc extract and application thereof in constipation treatment, relates to application of the sunflower disc extract prepared by modern technology and process for improving constipation, discloses a preparation method of the extract, and belongs to the technical field of food, health food and medicine production.
Technical Field
Constipation is a common complex symptom in clinic, and mainly refers to reduction of defecation frequency, reduction of stool quantity, dry and hard stool, difficult defecation and the like. Constipation is mild or severe in extent, and may be temporary or permanent in time. Constipation is a chronic digestive tract symptom, is very common in clinic and even exceeds other digestive tract symptoms, and clinical data show that constipation is a common symptom for the elderly, and constipation appears in about 1/3 elderly. However, with the increase of patients with constipation, not only the elderly and women, but also children with constipation in recent years are a big problem which troubles parents and clinics. The harm caused by constipation is also attracting more and more attention, particularly, constipation is one of the causes of death of patients with cardiovascular and cerebrovascular diseases, and sudden death of toilets occurs in recent years, and clinical attention has been paid.
At present, the types of medicines for treating constipation are various, but the medicines have good effects and few medicines without toxic or side effects, for example, the medicines for treating constipation by chemical medicines have certain adverse reactions, and can only be used for relaxing bowels by purgative medicines, and the medicines with the functions of relaxing bowels and purgation are taken, so that the vital qi of a human body can be consumed by the purgative medicines after long-term taking, the failure of intestinal motility is aggravated, and the malignant circulation is caused by the dependence of medicines of most patients. In addition, prolonged use of cathartics to relieve constipation can also lead to constipation when they are no longer taken. Therefore, early prevention and rational treatment of constipation will greatly reduce the serious consequences and social burden associated with constipation. With the improvement of modern living standard, people expect higher and higher quality of life, and pay more attention to some functional diseases which are ignored frequently.
At present, no literature reports about the application research of the sunflower disc extract for treating constipation.
Disclosure of Invention
The invention provides a sunflower disc extract, which comprises the process technologies of the ratio of sunflower discs to various enzymes, the reaction temperature, the reaction time and the like in the extraction process. The invention discloses a new function of a sunflower disc extract in treating constipation through a new preparation process.
The invention further discloses application of the sunflower disc extract in treating constipation, provides an effect of a single raw material of the sunflower disc on human body constipation, and has an obvious effect.
The invention relates to a preparation method of a sunflower disc extract, which is prepared by the following processes:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 10-20 times of water by weight, soaking for 1-4h, heating to 40-60 ℃, adding 0.25-0.5 part of cellulase, reacting for 1h, adding sodium carbonate, adjusting the pH to be =9, stirring uniformly, adding 0.25-0.5 part of alkaline protease, reacting for 1-2h, adding 0.25-0.5 part of neutral protease, reacting for 1-2h, adding 0.25-0.5 part of flavourzyme, reacting for 1-2h, filtering while hot, concentrating, and spray-drying to obtain powder or preparing particles by a granulator.
The preferred process comprises the following steps: weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 20 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding 0.5 part of cellulase, reacting for 1 hour, adding sodium carbonate, adjusting the pH to =9, stirring uniformly, adding 0.5 part of alkaline protease, reacting for 1 hour, adding 0.5 part of neutral protease, reacting for 1 hour, adding 0.25 part of flavourzyme, reacting for 1 hour, filtering while hot, concentrating, and preparing particles by using a granulator.
The invention has the positive effects that:
the extraction rate of small molecular peptides and polysaccharides in the prepared sunflower disc extract is greatly increased; proved by animal tests and population trials, the sunflower disc extract can treat constipation, promote defecation of patients and has no toxic or side effect.
Detailed Description
The present invention is further illustrated by the following examples, which do not limit the present invention in any way, and any modifications or changes that can be easily made by a person having ordinary skill in the art to the present invention will fall within the scope of claims of the present invention without departing from the technical solution of the present invention, which is achieved by the following techniques.
Example 1:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 10 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding 0.25 part of cellulase, reacting for 1 hour, adding sodium carbonate, adjusting the pH to =9, stirring uniformly, adding 0.25 part of alkaline protease, reacting for 1 hour, adding 0.25 part of neutral protease, reacting for 1 hour, adding 0.25 part of flavourzyme, reacting for 1 hour, filtering while hot, concentrating, spraying and drying to obtain powder.
Example 2:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 12 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding 0.5 part of cellulase, reacting for 1 hour, adding sodium carbonate, adjusting the pH to =9, stirring uniformly, adding 0.25 part of alkaline protease, reacting for 1 hour, adding 0.25 part of neutral protease, reacting for 1 hour, adding 0.25 part of flavourzyme, reacting for 1 hour, filtering while hot, concentrating, and preparing particles by using a granulator.
Example 3:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 15 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding 0.5 part of cellulase, reacting for 1 hour, adding sodium carbonate, adjusting the pH to =9, stirring uniformly, adding 0.5 part of alkaline protease, reacting for 1 hour, adding 0.25 part of neutral protease, reacting for 1 hour, adding 0.25 part of flavourzyme, reacting for 1 hour, filtering while hot, concentrating, and preparing particles by using a granulator.
Example 4:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 20 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding 0.5 part of cellulase, reacting for 1 hour, adding sodium carbonate, adjusting the pH to =9, stirring uniformly, adding 0.5 part of alkaline protease, reacting for 1 hour, adding 0.5 part of neutral protease, reacting for 1 hour, adding 0.25 part of flavourzyme, reacting for 1 hour, filtering while hot, concentrating, and preparing particles by using a granulator.
Comparative example 1:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 20 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding sodium carbonate to adjust the pH to be =9, uniformly stirring, adding 0.5 part of alkaline protease to react for 0.5 hour, adding 0.5 part of neutral protease to react for 0.5 hour, adding 0.5 part of flavourzyme to react for 0.5 hour, filtering and concentrating while hot, and preparing granules by using a granulator.
Comparative example 2:
weighing 1 part of powdered sunflower disc, mixing the weighed powdered sunflower disc with 20 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding sodium carbonate to adjust the pH to be =9, uniformly stirring, adding 0.5 part of alkaline protease, adding 0.5 part of neutral protease to react for 0.5 hour, reacting for 0.5 hour, filtering and concentrating while hot after reacting for 1.5 hours, and preparing granules by using a granulator.
The following experiments are used to further illustrate the therapeutic effect of the present invention:
1. animal experiment of bowel relaxing function of sunflower disc extract
1.1 Experimental animals: adult male Kunming mice, weighing 18-22g, were treated with 10 mice per group.
1.2 dose grouping and time of test sample administration: three dose groups were set for the experiment, as well as a blank control group and a model control group. Three dose groups are set according to 5 times, 10 times and 30 times of the recommended daily human body amount of 7.5g/70kg (0.107 g/kg), and the doses of the three dose groups are respectively 0.536 g/kg in the low dose group, 1.070 g/kg in the medium dose group and 3.210 g/kg in the high dose group. The tested sample is subjected to intragastric administration at the ratio of 0.1ml/10g · bw, and distilled water is supplied to the blank control group and the model control group by intragastric administration in the same way. The test samples were given for 7 days.
1.3 Experimental results:
(1) defecation function defecation time, stool particle count and stool weight, see table 1:
TABLE 1 determination of defecation time, stool particle count and stool weight: (
Figure 21145DEST_PATH_IMAGE002
± s, n=10）
Grouping Body weight (g) Defecation time (min) Number of stool grains (pieces) Stool weight (g)
Blank control group 23.3±1.20bcde 107.9±32.73bcde 24.6±4.86bcd 0.5813±0.15bd
Model control group 21.8±0.59acde 154.3±26.46acd 15.5±3.37ace 0.3556±0.15ac
Low dose group 20.3±1.60ab 187.3±32.95abe 11.7±5.81abd 0.2878±0.20bd
Middle dose group 19.7±2.07ab 171.8±25.43abe 19.4±2.56ace 0.4754±0.10ace
High dose group g 20.3±1.85ab 133.3±12.97acd 22.7±2.71bc 0.5138±0.15c
a = P <0.05 difference was statistically significant compared to the blank control group; b = statistical significance for P <0.05 differences compared to model groups; c = P <0.05 difference was statistically significant compared to the low dose group; d = statistically significant P <0.05 difference compared to the medium dose group; e = statistical significance of the difference P <0.05 compared to the high dose group.
The invention has the following statistical analysis results:
1) body weight
The differences between the model group, the low dose group, the medium dose group and the high dose group and the blank group were statistically significant; the blank, low, medium and high dose groups were compared to the model group, and the differences were statistically significant; the blank and model groups were statistically significant in difference compared to the low dose group; the blank and model groups were compared to the medium dose group, and the differences were statistically significant; the blank and model groups were compared to the high dose group, and the differences were statistically significant;
2) defecation time
The differences between the model group, the low dose group, the medium dose group and the high dose group and the blank group were statistically significant; the blank group, the low dose group, the medium dose group and the model group are compared, and the difference has statistical significance; the blank, model and high dose groups were statistically different from the low dose group; the blank, model and high dose groups were statistically different from the medium dose group; the low, medium and high dose groups were statistically significant compared to differences;
3) number of feces
The differences were statistically significant for the model group, the low dose group and the medium dose group compared to the blank group; the blank, low and high dose groups were statistically different from the model group; the blank, model and medium dose groups were statistically different from the low dose group; the blank, low and high dose groups were statistically different from the medium dose group; the difference between the model group and the middle dose group compared with the high dose group is statistically significant;
4) weight of feces
The differences between the model group and the medium dose group and the blank group were statistically significant; the blank group and the low dose group were statistically different from the model group; the difference between the model group and the middle dose group compared with the low dose group was statistically significant; the blank and low dose groups were statistically different from the medium dose group; the difference between the medium dose group and the high dose group was statistically significant.
(2) The results of the small bowel movements are shown in table 2:
grouping Body weight (g) Ink push Rate (%) Ink conversion (%)
Negative control group 29.3±3.79 0.72±0.11b 57.95±6.82bcde
Model control group 26.5±0.88a 0.48±0.13a 43.66±6.78ade
Low dose group 28.1±1.72 0.49±0.11a 45.85±15.43ade
Middle dose group 28.0±1.83 0.83±0.09ab 68.12±9.29abc
High dose group 27.8±2.67 0.86±0.15b 69.32±11.63abc
Table 2 results of small bowel movements experiment (
Figure DEST_PATH_IMAGE003
± s, n=10）
a: p <0.05 compared to the negative control group. b: p <0.05 compared to model control. c: p <0.05 compared to the low dose group. d: p <0.05 compared to the medium dose group. e: p <0.05 compared to the high dose group.
And (4) counting and analyzing results:
ink propulsion rate: the differences between the model control group, the low dose group and the medium dose group compared with the negative control group have statistical significance, and p is less than 0.05. The difference between the medium dose group and the high dose group compared with the model control group has statistical significance, and p is less than 0.05.
Conversion rate of ink: the differences between the model control group, the low dose group, the medium dose group and the high dose group and the negative control group have statistical significance, and p is less than 0.05. The negative control group, the medium dose group and the high dose group have statistical significance in comparison with the model control group, and p is less than 0.05. The negative control group, the medium dose group and the high dose group were statistically different from the low dose group with p < 0.05. The negative control group, the model control group and the difference of 0.1667g/kg compared with the medium dose group have statistical significance, and p is less than 0.05. The negative control group, model control group and low dose group had statistical significance for the differences compared to the high dose group, with p < 0.05.
1.4 cathartic function result judgment:
(1) the weight of defecation at 5 hours in the low dose group is significantly higher than that in the model control group, and p is less than 0.05; the dose groups of the low-dose group and the high-dose group with the number of the defecation granules in 5 hours are obviously higher than those of the model control group, and have significant difference, and p is less than 0.05. The result of the animal experiment is positive.
(2) The dose groups in the ink propulsion rate and the ink conversion rate and the high dose groups in the small intestine movement experiment are obviously higher than those in the model control group, the difference has statistical significance, and p is less than 0.05; the defecation time low dose group and the defecation time medium dose group are obviously higher than that of the model control group, the difference is statistically significant, and p is less than 0.05. The result of the animal experiment is positive.
2. Human body test of bowel relaxing function of sunflower disc extract
105 persons with constipation are searched (the volunteers of the invention consist of 50 women in 25-70 years old and 55 men in 30-60 years old, and have no intractable incurable population, and the individual difference does not affect the statistics), the group is divided into 7 groups, each group comprises 15 persons, 4 groups are implementation case experimental groups, 2 groups are control groups, and 1 group is a group which does not receive any treatment. The experimental group insists on taking the granules for 7 days, volunteers take the granules before lunch and dinner every day, the defecation habits of the volunteers are observed, and if the change is cured in the middle, the administration is stopped.
And (3) evaluating the curative effect:
the patient is cured, namely the constipation symptom disappears, and the defecation condition is recovered to be normal;
the composition has obvious effects that the constipation symptom of a patient is obviously improved but not completely normal, the defecation interval time is shortened by 1 day or more than 1 day, or the stool quality is improved, and other symptoms are obviously improved;
the constipation symptom of the patient is not changed and even has the tendency of aggravation.
Effective rate = (cure + show effect)/total number of samples;
the results of the experiments are shown in the following table:
TABLE 3 results of human body test
Cure of disease Show effect Invalidation High efficiency
Example 1 7 3 5 66%
Example 2 6 4 3 80%
Example 3 7 5 3 80%
Example 4 9 4 3 86%
Comparative example 1 6 3 6 60%
Comparative example 2 5 4 5 60%
Group not administered 1 1 13 13%
As can be seen from the table, after the volunteers took the sunflower disc extract prepared by the present invention, the treatment effect was better than that of the control group without taking the sunflower disc extract, examples 2, 3 and 4 showed better, example 4 had the most number of cured people and the least number of invalid people, so the process conditions of example 4 were selected as the best invention. The comparative examples 1 and 2 are inferior to examples 1, 2, 3 and 4, and the therapeutic effect is more excellent within the process range required by the present invention.

Claims (1)

1. A sunflower disc extract with constipation disease treating effect comprises the following steps:
weighing 1 part of powdery sunflower disc, mixing the weighed powdery sunflower disc with 20 times of water by weight, soaking for 1 hour, heating to 45 ℃, adding 0.5 part of cellulase, reacting for 1 hour, adding sodium carbonate, adjusting the pH to =9, stirring uniformly, adding 0.5 part of alkaline protease, reacting for 1 hour, adding 0.5 part of neutral protease, reacting for 1 hour, adding 0.25 part of flavourzyme, reacting for 1 hour, filtering while hot, concentrating, and preparing particles by using a granulator.
CN202010409447.XA 2020-05-14 2020-05-14 Sunflower disc extract and medical application thereof in constipation treatment Expired - Fee Related CN111419891B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010409447.XA CN111419891B (en) 2020-05-14 2020-05-14 Sunflower disc extract and medical application thereof in constipation treatment
AU2020101274A AU2020101274A4 (en) 2020-05-14 2020-07-07 Sunflower disc extract and medical use thereof in the treatment of constipation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010409447.XA CN111419891B (en) 2020-05-14 2020-05-14 Sunflower disc extract and medical application thereof in constipation treatment

Publications (2)

Publication Number Publication Date
CN111419891A CN111419891A (en) 2020-07-17
CN111419891B true CN111419891B (en) 2021-12-28

Family

ID=71553328

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010409447.XA Expired - Fee Related CN111419891B (en) 2020-05-14 2020-05-14 Sunflower disc extract and medical application thereof in constipation treatment

Country Status (2)

Country Link
CN (1) CN111419891B (en)
AU (1) AU2020101274A4 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114468104A (en) * 2021-12-30 2022-05-13 潘哒鲁鲁(深圳)生物科技有限公司 Functional candy with specific gastrointestinal regulation effect and industrial production method thereof
CN114377050A (en) * 2022-02-15 2022-04-22 吉林大学 Anti-gout composition containing sunflower disc micromolecules
CN115161123B (en) * 2022-07-21 2024-05-10 陕西中烟工业有限责任公司 Cleaning agent for cleaning tobacco stems and preparation method and application thereof
CN116808172B (en) * 2023-01-07 2024-02-13 龚曙初 Sunflower disc peptide, composite liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241259A1 (en) * 2003-05-29 2004-12-02 Christina Lim Herbal ointment and method for constipation treatment
CN103073657B (en) * 2013-01-15 2015-08-19 中北大学 A kind of Sunflower Receptacle low-fat pectin production method

Also Published As

Publication number Publication date
AU2020101274A4 (en) 2020-08-13
CN111419891A (en) 2020-07-17

Similar Documents

Publication Publication Date Title
CN111419891B (en) Sunflower disc extract and medical application thereof in constipation treatment
KR101734960B1 (en) Leuconostoc holzapfelii stain for preventing depilation, improving hair growth or improving sexual disfunction, and composition comprising the same
CN114097917A (en) Tabletting candy for relaxing bowels and preparation method thereof
KR102004346B1 (en) Composition for preventing depilation or improving hair growth comprising a stain having lipolysis ability
KR101790548B1 (en) Composition for preventing depilation or improving hair growth comprising a stain having lipolysis ability
Godding Laxatives and the special role of senna
KR102000170B1 (en) Food compositions for reducing body fat and improving intestinal function
CN108245531B (en) Composition for improving gastrointestinal tract function and preventing and treating constipation
CN109700833B (en) Pharmaceutical composition for treating constipation and preparation method and application thereof
TWI693939B (en) Composition for invigorating kidney and strengthening yang, preparation method and application thereof
CN113080450A (en) Health food for inhibiting and killing helicobacter pylori and preparation method thereof
CN103055155B (en) Traditional Chinese medicine for treating nasopharyngeal carcinoma and preparation method thereof
Widjanarko et al. Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats
JP2014155489A (en) Composition for preventing and treating diabetes, containing smilax china l. leaves extract
CN104306676A (en) Traditional Chinese medicine or health product for treating postnatal constipation
CN109865123A (en) A kind of pharmaceutical composition and its preparation method and application for treating recurrent oral ulceration
CN110801010A (en) Composition and health food for preventing and treating constipation
CN104225036A (en) Application of traditional Chinese medicine composition in preparation of drug for treating urinary system infection
CN103100079A (en) Compound medicine for treating infantile diarrhea and preparation method of compound medicine
KR102362024B1 (en) Composition for anti-obesity comprising phenylpropionylglycine
KR102407946B1 (en) Composition For Improving Bowel Movement Comprising Mimela splendens Larva or Extract Thereof
CN108245604A (en) A kind of composition of relief of constipation and preparation method thereof and purposes
KR101882303B1 (en) Composition for preventing depilation or improving hair growth comprising a stain having lipolysis ability
CN101829168B (en) Pharmaceutical composition for treating condyloma acuminatum and herpes, as well as preparation method thereof
CN100540046C (en) The mixture of agkistrodon acutus venom and Chinese herbal medicine extract and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211228

CF01 Termination of patent right due to non-payment of annual fee